EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Oral supplementation with crocin (a constituent of saffron) in subjects with cigarette smoking: a clinical trial

Mojtaba Mahdavi, Amir Ghaderi, Pooya Hazegh, Mohammad Hassan Karimipour Baseri, Neda Vahed, Shekoofeh Nazemi, Ali Aghajani, Fatemeh Sadat Ghoreishi, Hamidreza Sadeghi-Gandomani, Amene Taghdisi Kashani

Naunyn-Schmiedeberg's Archives of Pharmacology · 2024-08 · 397 (8) · 5689-5699

DOI: 10.1007/s00210-024-02970-7 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 31.01.2024. Verfasst von Mojtaba Mahdavi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Addiction Studies, School of Medical, Kashan University of Medical Sciences, Kashan, Iran. Hauptthemen laut MEDLINE: Carotenoids, Crocus, Dietary Supplements, Cigarette Smoking. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 75 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Smoking is one of the main causes of death in the world. Cigarette use is related with various components of metabolic syndrome (e.g., insulin resistance, raised blood pressure, dyslipidemia, oxidative stress, inflammation state) and psychiatric disorders. This study was conducted to determine the effect of crocin (Cro) supplementation on nicotine dependence, anxiety, depression, and metabolic indices in smokers. A total of 50 smokers were selected and randomly categorized into two groups (crocin and placebo). The intervention group received crocin (30 mg per day; n = 25) and placebo (containing Avicel; n = 25) once a day. The primary (nicotine dependence, depression, and anxiety inventory) and secondary (metabolic indices) outcomes were assessed at the start of the intervention and after the 3 months. Multiple linear regression models were used to assess the treatment effects on the outcomes adjusting for confounding variables. The primary outcome results such as nicotine dependence, depression, and anxiety inventory did not have a significant difference among the intervention groups (P > 0.05). Also in the secondary outcomes, fasting plasma glucose (FPG), insulin, and homeostasis model of assessment-insulin resistance (HOMA-IR) levels did indicate a significant difference by Cro intervention (β - 3.27 mg/dL; 95% CI, - 5.23, - 1.31; P = 0.002; β - 0.76 μIU/mL; 95% CI, - 1.38, - 0.15; P = 0.01; β - 0.18; 95% CI, - 0.29, - 0.07; P = 0.002), respectively. There were also significant reductions in serum levels of high-sensitivity C-reactive protein (hs-CRP) (β - 0.72 mg/L; 95% CI, - 1.37, - 0.07; P = 0.03), compared with the placebo. Cro intake may have favorable effects on the level of FPG, insulin, HOMA-IR, and hs-CRP in smokers. However, due to the small sample size and limited scientific reports on smokers, further studies are necessary. ClinicalTrial.gov Identifier: IRCT20170420033551N11.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarotenoidsCrocusDietary SupplementsCigarette SmokingHumansMaleFemaleAdultMiddle AgedDepressionDouble-Blind MethodTobacco Use DisorderInsulin ResistanceAnxietyBlood GlucoseAdministration, OralInsulinTreatment Outcome

Stichwörter der Autor:innen

AnxietyCigarette smokingCrocinDepressionMetabolic biomarkersNicotine dependence

Substanzen

crocinCarotenoidsBlood GlucoseInsulin

Autor:innen und Institutionen

  • Department of Addiction Studies, School of Medical, Kashan University of Medical Sciences, Kashan, Iran.
  • Department of Addiction Studies, School of Medical, Kashan University of Medical Sciences, Kashan, Iran. gaderiam@gmail.com.
  • Clinical Research Development Unit-Matini, Kargarnejad Hospital, Kashan University of Medical Sciences, Kashan, Iran. gaderiam@gmail.com.
  • Department of Psychiatry, Kashan University of Medical Sciences, Kashan, Iran.
  • Department of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Research Center for Addiction and Risky Behaviors (ReCARB), Psychosocial Health Research Institute, Iran University of Medical Sciences, Tehran, Iran.

Zitieren

APA

Mahdavi, M., Ghaderi, A., Hazegh, P., Baseri, M. H. K., Vahed, N., Nazemi, S., Aghajani, A., Ghoreishi, F. S., Sadeghi-Gandomani, H., & Kashani, A. T. (2024). Oral supplementation with crocin (a constituent of saffron) in subjects with cigarette smoking: a clinical trial. Naunyn-Schmiedeberg's Archives of Pharmacology, 397(8), 5689-5699. https://doi.org/10.1007/s00210-024-02970-7

Vancouver

Mahdavi M, Ghaderi A, Hazegh P, Baseri MHK, Vahed N, Nazemi S, et al. Oral supplementation with crocin (a constituent of saffron) in subjects with cigarette smoking: a clinical trial. Naunyn-Schmiedeberg's Archives of Pharmacology. 2024;397(8):5689-5699. doi:10.1007/s00210-024-02970-7

BibTeX
@article{Mahdavi2024,
  author = {Mahdavi, Mojtaba and Ghaderi, Amir and Hazegh, Pooya and Baseri, Mohammad Hassan Karimipour and Vahed, Neda and Nazemi, Shekoofeh and Aghajani, Ali and Ghoreishi, Fatemeh Sadat and Sadeghi-Gandomani, Hamidreza and Kashani, Amene Taghdisi},
  title = {Oral supplementation with crocin (a constituent of saffron) in subjects with cigarette smoking: a clinical trial},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2024},
  volume = {397},
  number = {8},
  pages = {5689--5699},
  doi = {10.1007/s00210-024-02970-7}
}
Kostenlos starten →